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Proteomic mapping of differentially 
vulnerable pre-synaptic 
populations identifies regulators of 
neuronal stability in vivo
Maica Llavero Hurtado1, Heidi R. Fuller2, Andrew M. S. Wong3, Samantha L. Eaton1, Thomas 
H. Gillingwater  4, Giuseppa Pennetta4,5, Jonathan D. Cooper3,6 & Thomas M. Wishart1,5
Synapses are an early pathological target in many neurodegenerative diseases ranging from well-
known adult onset conditions such as Alzheimer and Parkinson disease to neurodegenerative 
conditions of childhood such as spinal muscular atrophy (SMA) and neuronal ceroid lipofuscinosis 
(NCLs). However, the reasons why synapses are particularly vulnerable to such a broad range of 
neurodegeneration inducing stimuli remains unknown. To identify molecular modulators of synaptic 
stability and degeneration, we have used the Cln3−/− mouse model of a juvenile form of NCL. We 
profiled and compared the molecular composition of anatomically-distinct, differentially-affected 
pre-synaptic populations from the Cln3−/− mouse brain using proteomics followed by bioinformatic 
analyses. Identified protein candidates were then tested using a Drosophila CLN3 model to study 
their ability to modify the CLN3-neurodegenerative phenotype in vivo. We identified differential 
perturbations in a range of molecular cascades correlating with synaptic vulnerability, including valine 
catabolism and rho signalling pathways. Genetic and pharmacological targeting of key ‘hub’ proteins 
in such pathways was sufficient to modulate phenotypic presentation in a Drosophila CLN3 model. 
We propose that such a workflow provides a target rich method for the identification of novel disease 
regulators which could be applicable to the study of other conditions where appropriate models exist.
Synapses are an early pathological target in a range of diseases1,2 including conditions associated with advanc-
ing age (e.g. Alzheimer (AD)3,4 and Parkinson disease5,6), neurodevelopmental conditions (e.g. spinal muscular 
atrophy (SMA)7,8), protein misfolding/accumulation diseases (e.g. Huntington disease (HD)9), prion diseases10, 
spinocerebellar ataxias (SCA)11 and lysosomal storage disorders (Neuronal ceroid lipofuscinosis (NCLs or Batten 
disease)12–16. However, our understanding of the reasons why specific synaptic populations are so vulnerable to 
such a broad range of neurodegenerative stimuli, and the mechanisms that govern their stability, remains in its 
infancy2,17,18.
In this study, we sought to define the molecular regulators of synaptic stability, using animal models of CLN3 
disease (a.k.a. juvenile NCL or JNCL, OMIM # 204200). The NCLs, are the most frequent autosomal-recessive 
neurodegenerative disease and form of dementia in childhood19. Incidence in the USA is estimated at 1.6–
2.4/100,000 whereas in Scandinavian countries it is 2–7/100,00020,21. The term “NCL” currently encompasses 
up to 14 disease subtypes, which are grouped together due the lysosomal accumulation of autofluorescent stor-
age material, distinct ultrastructural properties, broadly similar pathology and clinical features and a severe 
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neurodegenerative phenotype16,22. Crucially for the purposes of this study, pre-synaptic disruption is a key early 
event in NCL, accurately predicting the distribution of subsequent neuronal loss12–16.
The knowledge of the underlying genetic cause and/or storage material composition have provided a base for 
the basic understandying of the pathogenesis and their correlation to the clinical progression of the disease, the 
design of gene replacement therapies and the development of animal models23–25. However, the pathways and 
molecular cascades leading to neurodegeneration in NCL, as in many other neruodegenerative diseases, are still 
unknown.
Mutations in CLN3 underlie a juvenile form of NCL, the most prevalent form worldwide26. The CLN3 gene 
encodes a putative transmembrane protein whose function is not completely understood. However, experiments 
in yeast and in vitro studies have revealed possible functions relating to vacuolar pH regulation27 and endo-
cytic membrane trafficking28. Although CLN3 is ubiquitously expressed throughout the body, the most obviously 
affected tissues are neurologic based. This feature is shared by other monogenetic neurodegenerative conditions 
such as SMA29. Yet, the reasons why neurons appear to be particularly vulnerable to defects in such broadly 
expressed proteins is not understood.
In humans, the onset of CLN3 disease occurs typically between 4–7 years of age, when loss of visual acuity is 
identified. Learning deficits are followed by speech and motor difficulties and seizures. As no treatment is cur-
rently available, premature death results at a mean age of 24 years old30. Unlike other more complex neurodegen-
erative diseases, the growing knowledge of the NCL-causative genes has facilitated the development of powerful 
animal models in recent years. These models have significatively improved our understanding of the progressive 
nature of the different forms of NCL. Cln3 null mice (Cln3−/−) reproduce various aspects of the human disor-
der31,32. Although neuronal loss is widespread in terminal disease31,33, differential vulnerability can be detected 
across brain regions and their respective resident cell types/subcellular compartments at specific time-points. This 
differential degenerative progression follows the same pattern in the vast majority of NCL murine models: during 
pre-symptomatic stages there is an early selectivity for relay neurons within the thalamic nuclei followed by the 
corresponding cortical areas14,31–35, as well as GABAergic hippocampal interneurons and Purkinje neurons31,32. 
These reports in murine models regarding the vulnerability of the thalamus correlates with MRI studies in human 
patients showing alterations in thalamic areas at “pre-clinical” stages30,36,37. Furthermore, differential regional/
neuronal vulnerability is also a shared event in a great number of neurodegenerative diseases in which some brain 
regions seem affected earlier than others, such as in Alzheimer38–40, Parkinson41, Huntington diseases42,43.
In this study, we aimed to define the molecular regulators of both synaptic stability and vulnerability using 
animal models of NCL. We initially characterized differential patterns of pre-synaptic pathology in Cln3−/− 
mice31 across two different time-points. This enabled the subsequent application of high-throughput proteomics 
in order to map the molecular fingerprint of differentially vulnerable biochemically-isolated pre-synaptic pop-
ulations. We identify multiple cascades correlating with synaptic vulnerability and describe valine degradation 
and rho signalling pathways as two major regulators of synaptic vulnerability. The direct contribution of these 
pathways to neurodegeneration was confirmed in vivo using a Drosophila CLN3 model. Finally, we are confident 
that regulators of synaptic vulnerability and degeneration identified in the context of NCL are also conserved in 
their expression across other neurodegenerative conditions, in which pre-synaptic alterations are an early event2. 
This research therefore opens a window for further investigation into common molecular therapeutic targets 
and strategies for novel interventions across a range of neurodegenerative conditions during early disease onset.
Results
Quantitative immunohistochemistry identifies differential rates of pre-synaptic pathology 
between brain regions in Cln3−/− mice. Although the spatio-temporal pattern of neuron loss in Cln3−/− 
mice has already been studied32,33, little is known about the progression of synaptic pathology across differentially 
vulnerable brain regions. Studies in other NCLs using Ppt1−/−, Cln6−/− or CathD−/− mice have revealed progres-
sive synaptic loss starting in the thalamus and followed later in corresponding cortical areas12,14. Hippocampal 
structures seem to be also affected early, although to a lesser extent than seen in the thalamus33. To investigate 
whether a similar pattern of synaptic pathology might be present in Cln3−/− mice we studied the expression of the 
presynaptic marker synaptophysin (Syp; as previously described in12) in three brain regions that exhibit different 
degrees of neuronal vulnerability using quantitative immunohistochemistry (at 6.5 and 13 months; see methods 
– Fig. 1 and Supplementary Fig. S1). The three brain regions studied were: 1. Thalamus – ventral posteromedial/
ventral posterolateral nuclei (VPM/VPL) and lateral geniculate nucleus (LGNd); 2. The corresponding cortical 
target regions in the primary somatosensory barrel field (S1BF) and primary visual areas (V1) respectively, and 
3; Hippocampus- stratum radiatum and stratum oriens (Fig. 1A). At 6.5 months no significant changes in Syp 
expression were detected between Cln3−/− and control mice in any of the brain regions studied (Supplementary 
Fig. S1). However, by 13 months, some differences between genotypes were apparent (Fig. 1B and C). Similar to 
mouse models of other NCLs, thalamic nuclei demonstrated greater synaptic pathology at 13 months as indicated 
by the lower Syp immunoreactivity to synaptophysin in Cln3−/− vs. controls. Hippocampal structures were also 
affected, although as predicted, the difference in Syp immunoreactivity between genotypes in both hippocampal 
subfields was less than in thalamic nuclei. In contrast, cortical regions such as S1BF and V1 (corresponding to the 
thalamic nuclei VPM/VPL and LGNd) showed no statistical difference between genotypes in Syp immunoreac-
tivity at 13 months. Immunohistochemistry using antibodies against VAMP2 and SNAP-25 (two more pre-syn-
aptic markers) also hint at pre-synaptic alterations in the thalamus (Fig. S2–S4).
Thus, the pre-synaptic alterations seen here (as determined with the markers detailed above) appears to follow 
a similar pattern to that previously reported for neuronal loss in mouse models of other forms of NCL12,14, with 
the thalamus being the most affected region, followed by the hippocampus, whereas cortical measurements were 
still unaffected at this stage of disease. We would categorize these alterations in pre-synaptic markers as being 
moderate at 13 months, as the pathology as quantified here is less than 10% (9.57% relative to controls).
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Figure 1. Spatio-temporal synaptic loss study in Cln3−/− detected differentially vulnerable synaptic populations 
across brain regions. (A) Brain region schematic showing the brain areas measured in grey. Thalamic regions 
includes the ventral posterior medial/ventral posterior lateral thalamic nucleus (VPM/VPL) (top left) 
and the dorsal lateral geniculate nucleus (LGNd) (bottom left); their respective cortical projections in the 
primary somatosensory cortex (S1BF) (top right) and primary visual cortex (V1) respectively (bottom right); 
hippocampal regions measured within the CA1-3 were the stratum radiatum and stratum oriens (bottom). 
(B and C) Representative photomicrographs of coronal sections of the same brain regions immunostained 
with synaptophysin (Syp) and bar chart showing its corresponding quantification based on the area of 
immunoreactivity in 13 month old control and Cln3−/− mice. Syp immunoreactivity was lower in thalamic 
regions (VPM/VPL and LGNd) in the Cln3−/− mice when compared to controls indicating more pathology, 
detectable earlier in the thalamus. Hippocampal stratum oriens and stratum radiatum also showed reduced 
Syp immunostaining, although the difference between genotypes was smaller. Cortical regions did not show 
difference in immunoreactivity for synaptophysin indicating that no synaptic loss is happening in these cortical 
areas at 13 months. (Mean ± SEM; *P < 0.05; **P < 0.01; ***P < 0.001; ns P > 0.05, Student T test, 5 mice per 
each genotype and time-point were used, Scale bar = 200 um (left) and 20 um (right).
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Comparative molecular profiling reveals proteomic perturbations that correlate with the 
extent of pre-synaptic alterations. Despite advances in the characterization of the mammalian synaptic 
proteome, little is known about how these proteins interact and the molecular mechanisms that govern synaptic 
vulnerability. After confirming the synaptic vulnerability pattern across three distinct brain regions, we wanted to 
examine if the onset of pre-synaptic pathology correlated with distinct molecular alterations in the proteome. To 
address this, we examined biochemically isolated pre-synaptically enriched fractions (through the generation of 
“crude” synaptosomes – see methods) produced from microdissected brain regions from Cln3−/− mice and con-
trols at 13 months of age where we characterise the pre-synaptic pathology as thalamus > hippocampus > cortex.
After synaptosome production and protein extraction, iTRAQ proteomics was carried out as detailed in Fig. 2. 
1536 total proteins were identified in hippocampus and thalamic samples whereas 2068 were detected in cortex. 
We then pre-filtered the proteins by those which were identified by at least 2 peptides and therefore are more 
likely to be reliable identifications. 914 proteins passed that filter in hippocampus and thalamus and 1295 in 
cortex. Almost 40% of our pre-filtered thalamic proteome was altered when compared to control littermates. In 
contrast, only 20% and 17.6% of the synaptic proteome was altered in the cortex and hippocampus relative to 
controls respectively. The number of protein alterations also correlates with pre-synaptic pathology being more 
apparent in thalamic areas at this “moderate” stage of disease progression.
Figure 2. Experimental design workflow. Experiments are divided into in vivo (animal models), MS processing 
and in-silico where the different bioinformatics tools are detailed. *This schematic was reproduced for the three 
brain regions of interest: cortex, hippocampus, and thalamus at 13 months of age.
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Next, these pre-filtered proteins from the three pre-synaptic populations were aligned to look for overlapping 
proteins. 709 proteins were identified in all three brain regions and these were taken forward for comparative 
analysis (Fig. 3A).
In order to gain a broad and unbiased overview for the types of processes that may be represented by the 
protein alterations detected in all three pre-synaptic populations, we used Ingenuity pathway analysis (IPA) (see 
Methods – Fig. 3B). Interestingly, we identified multiple canonical pathways which IPA designated as perturbed 
in a strikingly progressive manner, consistent with the degree of pre-synaptic pathology outlined above i.e. −log 
P value = higher in thalamus > hippocampus > cortex (Fig. 3B). An example cascade can be found in more detail 
in Supplemetary Fig. S5. This analysis therefore indicates that in general, alterations in specific molecular cascades 
were increasing with pre-synaptic pathology, further confirming the differential vulnerability pattern previously 
identified by IHC. Thus, the synaptic vulnerability pattern described here appears consistent at both the morpho-
logical and that molecular level.
Whilst canonical cascade analysis is an interesting tool to use at the outset, multiple members of the same 
cascade do not necessarily need to change in the same manner, and whilst the trend of the majority of canonical 
cascades seen in Fig. 3B are consistent with the regional pathology reported, the individual protein alterations 
are far more complex (ass seen in the heatmap in Fig. 3C). Thus, to better understand and visualize the different 
molecular expression trends occurring across the three datasets, individual proteins were tracked using BioLayout 
Express 3D (see Methods). Simplistically, BioLayout is a complex pattern recognition software which generates a 
visual representation of the data based on protein abundance44. In this case the software interrogates a regional 
expression profile generated by arranging the individual proteomic sets in order of increasing pre-synaptic 
pathology/vulnerability (cortex < hippocampus < thalamus). The outcome of this is that proteins were found 
to cluster into 14 different groups according to similarities in their relative expression across these three regions 
(Fig. 3D)45. Of interest to us were Clusters 3 (70 proteins), 4 (68 proteins), 6 (51 proteins) and 7 (50 proteins) com-
prise proteins whose expression can be grouped (or clustered) together as having either a gradual upregulation or 
downregulation, therefore correlating (directly or inversely with) with pre-synaptic vulnerability (Fig. 3D and E, 
Supplementary Table S1). Next, we applied an enrichment analysis to these distinct clusters in order to determine 
if each expression trend could be associated with a specific biological or functional category (using the DAVID 
software tool – see methods and Fig. 3E). Unexpectedly, clusters with proteins that were increasingly upregulated 
in vulnerable regions were enriched for structural associated candidates like cytoskeletal-related proteins, and 
specific biological functions such as endocytosis (Cluster 4 and 7). Perhaps more surprisingly, clusters whose pro-
tein expression decreased with increasing vulnerability were related to specific mitochondrial functions (Clusters 
3 and 6) (Fig. 3D and E and Supplementary Table S2). Thus, comparative proteomic profiling of differentially 
vulnerable pre-synaptic populations revealed that significant alterations to the synaptic proteome correlated with 
the degree of pathology seen at these relatively moderate disease stages.
In silico analysis highlights alterations in valine catabolic and ROCK2 signalling cascades in 
vulnerable pre-synaptic compartments. After confirming that the pre-synaptic proteome changes in 
a manner consistent with the differential vulnerability/regional disease progression in Cln3−/− mice, we next 
sought to tease out the potential molecular regulators of neuronal stability from our complex proteomic datasets. 
To do this, we focused our analyses on the thalamus, because pre-synaptic compartments here were perturbed to 
a greater extent than those in the hippocampus or cortex (according to the pre-synaptic markers we employed). In 
the thalamic dataset, 1536 total proteins were identified following iTRAQ processing. Further DAVID enrichment 
analysis was applied to the unfiltered thalamic data to confirm that the starting material was suitably enriched 
for synaptic proteins (Table 1). As described above, we applied filtering criteria based on the number of pep-
tides (more than 2 unique peptides), those changed > 20% (1.2 fold-change) and those which were mapped by 
Ingenuity Pathway Analysis (IPA) software. A total of 374 proteins met these criteria (Fig. 4A and Supplementary 
Tables S3–S4). Next, we confirmed the veracity of the filtered data by validating a range of proteins using quanti-
tative fluorescent Western blotting (QWB) (Fig. 4B–G).
Higher order functional clustering highlights similarities with other neurodegenerative conditions. Here, we used 
ingenuity pathway analysis (IPA) to elucidate which molecular pathways and biological networks were disrupted 
in “affected” thalamic pre-synaptic compartments. Here we input the total pre-filtered thalamic data into IPA and 
applied the 1.2 fold-change cut-off in the software. Of the three-hundred and seventy-four proteins recognised by 
IPA, 68.3% have previously been reported in the literature as being associated with neurological disease (Fig. 5A). 
The majority of the diseases and disorders which fall under the category of “neurological disease” are known to 
demonstrate synaptic pathology as an early event1. Interestingly, the main molecular and cellular functions iden-
tified in IPA were “molecular transport” and “cellular assembly and organization”. These functional categories are 
consistent with the comparative analysis of differentially vulnerable synaptic populations carried out above (see 
Fig. 3E), where clusters showing increases in protein expression from the levels detected in the comparatively 
spared cortical synapses through to greater levels again in the more vulnerable thalamic populations highlighted 
cytoskeletal protein alterations.
Molecular cascade tracking identified potentially conserved regulators of vulnerability. The “Canonical pathways” 
function in IPA revealed that, mitochondrial dysfunction was the most significant canonical pathway identified 
(see Methods). The contribution of synaptic mitochondria in neurodegeneration has been highlighted in recent 
years46, and mitochondrial abnormalities have also been related to CLN3 disease and other NCLs47–50, and our 
data is therefore consistent with these previous findings. However, in this study we wanted to consider path-
ways that have not previously been related to the NCLs before. Within the top canonical pathways identified 
with IPA, we also detect perturbations in ROCK signalling and valine degradation pathways (Fig. 5B and C). 
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Figure 3. Differentially vulnerable synaptic population molecular profiling. (a) Venn diagram and heat map 
show the 709 common proteins identified and overlapped in cortical, hippocampus and thalamic synaptic 
proteomic datasets. (B) Heat map representing the significance (−log P value) of the canonical pathways 
identified in IPA across cortex, hippocampus and thalamus datasets. It is observed a preogressive increase in 
significance correlating to the synaptic vulnerability pattern described previously. (C) Heat map showing the 
709 common proteins identified and overlapping in cortical, hippocampus and thalamic synaptic proteomic 
datasets. (D) BioLayout clustering 3D representation of proteomic expression data across differentially vulnerable 
synaptic populations orientated at 3 different angles. Each sphere represents a single protein and the edge 
represents how similar their expression trend is towards the other proteins in the dataset. The closer the spheres 
are the more similar expression trend they have. The colours represent the different clusters of co-expressed 
proteins. (E) Expression profile means in log scale (Cln3−/−/WT) of co-expressed proteins in clusters 3, 4, 6 and 
7 (Supplementary Tables S1) and its main biological function/subcellular compartment identified by DAVID 
enrichment analysis (See Supplementary Table S2). Clusters highlighted show steady up or downregulation across 
cortex (C), hippocampus (H) and thalamic (T) regions correlating with the vulnerability status of synapses.
www.nature.com/scientificreports/
7SCIENTIfIC REPoRtS | 7: 12412  | DOI:10.1038/s41598-017-12603-0
Examining these pathways, proteins such as ROCK2 and HIBCH were differentially expressed key “hub” com-
ponents. Their expression was identified as tracking in BioLayout clusters 4 and 6 respectively correlating to the 
degree of pre-synaptic pathology in Cln3−/− mice (see above, Figs 3D and 5). Moreover, we have previously iden-
tified ROCK2 and HIBCH expression alterations in pre-synaptic striatal isolates following cortico-striatal lesion 
injury (Fig. 5E), and demonstrated their potential to alter neurodegeneration in an injury specific context in 
vivo2. Collectively these findings hinted that there may be a common molecular cascade underlying pre-synaptic 
pathology following a range of neurodegeneration inducing insults (from injury through to genetic). ROCK2 
signaling and valine degradation pathways and specifically proteins such as ROCK2 and HIBCH, could therefore 
represent potentially novel regulators of synaptic stability in an NCL disease context, which have not been inves-
tigated yet. So we next sought to determine if such candidates could have the ability to moderate NCL disease 
progression in vivo.
Targeting the valine catabolic cascade is sufficient to modulate CLN3-induced neurodegener-
ation in vivo. HIBCH is a 3-hydroxyisobutyryl-CoA hydrolase protein that fulfils a core function within the 
valine degradation cascade51. Mutations in HIBCH cause a progressive infantile neurodegeneration in humans, 
characterized by hypotonia, motor delay and neurological regression51–53. Moreover, manipulation of HIBCH 
has been suggested to modulate injury-induced axonal degeneration2. However, despite this apparently restricted 
function, very little is known about its role (if any) in synaptic compartments or its binding/interaction partners 
(see Fig. 6A).
Using QWB techniques we confirmed that HIBCH protein was less abundant in “crude” synaptosome extracts 
from thalamus in Cln3−/− mice relative to wild type controls. Interestingly, HIBCH protein levels trended 
towards a slight up-regulation of HIBCH in “non-synaptic” compartments. Whilst not statistically significant, 
this non-synaptic increase may indicate a redistribution or altered trafficking of this protein in response to Cln3 
deficiency (Fig. 6B). Importantly, examination of human post mortem brain samples showed that HIBCH protein 
levels were significantly reduced in JNCL patients (Fig. 6C).
From comparing synaptic vulnerability (Fig. 3), HIBCH belonged to Cluster 6 (gradual downregulation 
profile) and was co-expressed with other mitochondria-related proteins (Fig. 3E) including Hydroxyacyl-CoA 
Dehydrogenase/3-Ketoacyl-CoA Thiolase/Enoyl-CoA Hydratase (Trifunctional Protein), Alpha Subunit 
(HADHA), which also fulfils an enzymatic role within the valine degradation pathway (Fig. 6D). HADHA sits 
upstream of HIBCH in the valine catabolism cascade (Fig. 6E) and catalyzes the final three steps of mitochondrial 
long chain fatty acid β-oxidation54. HADHA codes for the α subunit of the mitochondrial trifunctional protein 
(αMTP), and its deficiency causes a metabolic disease that presents with Reye-like syndrome, with cardiomyopa-
thy, neuromyopathy and sudden death in infancy55. More recent reports have indicated that HADHA deficiency 
results in a pigmentary retinopathy leading to vision loss56.
Given the important role of these two proteins in the valine catabolism cascade, we wanted to explore the con-
sequences of experimental suppression of HIBCH and HADHA levels in vivo in order to assess their influence on 
synaptic and neuronal stability in an NCL-disease specific context. To do so, we used a CLN3 gain of function fly 
model previously characterized by Tuxworth et al. in which the Drosophila eye undergoes degeneration (becom-
ing smaller and rougher)57. Although this is an accepted model for investigations into the cascades underpinning 
CLN3, the human disease is normally caused by loss of function. As with the human disease where dose is crucial 
to phenotype (i.e. heterozygous humans are not obviously affected) we can also demonstrate that degeneration 
ocuring in the Drosophila eye is CLN3 dose dependent (Fig. S6) as is the case for other neurodegeneration asso-
ciated proteins (i.e. TDP43)58.
Thus, using this Drosphila model as a rapid screen for candidate ability to effect CLN3 driven phenotype 
(whilst bearing in mind its potential limitations) we first established a recombinant fly containing the GMR-GAL4 
eye driver and the UAS-CLN3 gene in the second chromosome (GMR-GAL4;UAS-CLN3/CyOGFP, see Table 2), 
and crossed this with fly lines containing RNA interference (RNAi) of HIBCH and HADHA mouse orthologs. 
CG5044 and CG4389/MTPα orthologs were selected using the DRSC Integrative Ortholog Prediction Tool 
(DIOPT) (see Methods and Table 2). Progeny of the relevant genotype was counted (GMR-GAL4;UAS-CLN3/
HibchRNAi and GMR-GAL4;UAS-CLN3/MTPαRNAi), eyes photographed and total surface area measured with 
Term
Fold 
Enrichment P-Value Benjamini
Clathrin coat of coated 
pit 20.5 9.30E-02 2.70E-01
Synaptic vesicle 
membrane 9.7 3.70E-02 1.50E-01
Synaptic vesicle 8.2 1.30E-05 1.20E-04
Dendritic spine 6.8 7.00E-02 2.20E-01
Presynaptic membrane 6.6 7.50E-02 2.30E-01
Axon 5.2 3.40E-04 2.50E-03
Mitochondrial inner 
membrane 5.2 7.10E-11 1.90E-08
Synaptosome 4.7 2.20E-02 9.50E-02
Synapse 4.1 2.20E-07 4.30E-06
Table 1. DAVID analysis of proteomic data confirms synaptic protein enrichment.
www.nature.com/scientificreports/
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Image J (see Methods). As expected, experimental suppression of either HIBCH or HADHA increased the neu-
rodegenerative phenotypes observed (i.e. acting as enhancers of the CLN3-dependent phenotype) (Fig. 6F and 
G). Interestingly, the further upstream the valine degradation cascade is disrupted, the greater the effect on CLN3 
phenotype (Fig. 6H). Interestingly, in this context neither HIBCH or HADHA were able to cause degeneration in 
the eye in the absence of the CLN3 disease background (Supplementary Fig. S7). This suggests that their manip-
ulation alone is not sufficient to affect general neuronal stability, and that the effect seen when crossing HIBCH 
and HADHA with the CLN3 fly is likely mediated by the CLN3 allele. As such HIBCH and HADHA appear to be 
in vivo modifiers of neuronal stability in a CLN3-disease context, and this provides further evidence that valine 
catabolism may play a role in CLN3-dependent neurodegeneration.
Increased pre-synaptic ROCK2 expression appears conserved across a range of diseases and its 
downregulation can reduce CLN3-induced neurodegeneration in vivo. As discussed above, ROCK 
cascades were also identified as being perturbed in degenerating thalamic pre-synaptic compartments and were 
predicted (by in silico analysis) to be activated when compared to wildtype controls (Fig. 5B and C). ROCK2 is 
a Rho-kinase belonging to a family of serine/threonine kinases, of which isoform 2 is the most predominant in 
the brain59. ROCK2 directly interacts with, and is activated by, Rho GTPases. These are the central mediators of 
actin reorganization59, which are reported to have a key role in synaptic plasticity and long term potentiation60. 
Activation of ROCK2 has been implicated in several adult-onset neurodegenerative conditions where synaptic 
pathology is present, such as HD, AD, ataxia, and in Purkinje cell degeneration2,61–64. Moreover, ROCK2 has been 
shown to influence childhood neurodegenerative conditions such as SMA, where pharmacological inhibition 
partially recued symptoms and increases lifespan in an SMA mouse model65,66. Moreover, we have previously 
reported that ROCK2 is capable of influencing axonal degeneration in vivo following injury2. Taken together 
with our current data, this is consistent with a model whereby upregulation/activation of ROCK2 signalling in 
pre-synaptic compartments may correspond with increased neuronal vulnerability or degeneration in multiple 
infantile- and late-onset neurodegenerative conditions (Fig. 7D).
The ROCK2 interactome (displayed in Fig. 7A) illustrates its reported interactions with other gene/proteins, 
many of which were also altered in Cln3−/− thalamic synaptic extracts. In the Cln3−/− thalamus, QWB con-
firmed that ROCK2 was upregulated by 53.7% in the synaptic fractions, and by 27.7% in the corresponding “non 
Figure 4. Synaptic thalamic proteome filtering and validation. (A) Dot plot demonstrating the process of 
proteomic data filtering. Each data point represents an individual protein identified using iTRAQ proteomic 
technique. LHS 1536 proteins were identified across all thalamic samples. Following filtering (see Methods) a 
molecular fingerprint for thalamic synaptic alterations comprising 374 candidate proteins was produced (RHS; 
see also Supplementary Tables S3 and S4). (B) QWB representative bands for two upregulated (β-catenin and 
ROCK2), two downregulated (HIBCH and α-synuclein) and one unchanged protein candidate (calretinin) 
verifying the proteomic data. (C and G). Quantification and statistical QWB analysis showing the magnitude of 
alteration in Cln3−/− thalamic synaptic fractions. All the selected candidate proteins were altered as indicated by 
this iTRAQ analysis. Mean ± SEM; *P < 0.05; ***P < 0.001 (Student T test, n = 6 mice per each genotype).
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Figure 5. IPA analysis of the thalamic synaptic proteome. (A) Table of top 5 “diseases and disorders” and 
“molecular and cellular functions”. (B and C) Canonical pathways bar chart of representative pathways showing, 
(B) The percentage of upregulated and downregulated proteins within each pathway. Numbers on the top 
indicate the total number of proteins within the canonical pathway. (C) Significance of the association between 
the dataset and the canonical pathway (−log(p-value) and ratio) and z-score prediction of activation/inhibition 
(see Methods). Pathways highlighted in green and blue are associated to ROCK2 and HIBCH, respectively. 
(D) HIBCH and ROCK2 protein expression ratio across cortex (“less affected’) and thalamic (“degenerating”) 
synapses in these moderately affected Cln3−/− mice (Cln3−/−/WT). (E) HIBCH and ROCK2 protein expression 
is conserved in models of injury, following similar pattern of expression 24 hours post-injury when synapses 
start to degenerate2.
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Figure 6. CLN3 induced degeneration is enhanced by the genetic downregulation of HIBCH and HADHA in 
vivo impacting in valine catabolism pathway. (A) HIBCH proteome interactome represented by IPA indicating 
only 6 gene/proteins are known to interact with HIBCH. (B) QWB bands and quantification of HIBCH in 
synaptic and “non synaptic” fractions of Cln3−/− and control mice in thalamic protein extracts showing a 
downregulation in synapses and upregulation in non-synaptic parts **P < 0.01, ns P > 0.05 (Student T test). 
(C) QWB bands and quantification of cortical “crude” synaptosomes isolated from post mortem human JNCL 
patients (P) and controls (C) showing its downregulation at end stages in human disease *P<0.05 (Student 
T test). (D) HIBCH and HADHA are co-expressed and their expression trend correlates to the vulnerability 
status of synapses: unchanged in cortex (“spared”) and downregulated in thalamus (“degenerating”). (E) Valine 
degradation pathway represented with IPA. The first protein which expression is perturbed in the degradation 
process of valine is HADHA; upstream of HIBCH. (F–G) Representative light microscope images of Drosophila 
eyes of disease model (DM), DM + HIBCH RNAi and DM + HADHA RNAi and corresponding quantification 
of the eye surface area. Scale bar = 100um. ***P < 0.001 (One-way ANOVA and Tukey’s multiple comparison 
test as a post-hoc). (H) Schematic representation of the fourth and fifth steps of the valine catabolism cascade 
showing the enzymes HADHA and HIBCH catalyzing each step respectively. (A,E & H) Colored nodes 
illustrate proteins present in the thalamic dataset in Cln3−/− with respect WT. Nodes in grey represent proteins 
changed <20%, down-/up-regulated proteins by >20% are represented in green and red respectively. Orange 
box highlights the steps that are disrupted in the valine degradation cascade. Dotted lines on representative 
westerns indicate cropping of bands from the same membrane.
Line Source Description
Canton S BDSC Wild type line
GMR-GAL4 BDSC Eye expression driver
UAS-CLN3 Tuxworth et al. 2009 CLN3 overexpression
GMR-GAL4;UAS-CLN3/CyO GFP This study Recombinant line
Candidate lines Source Genotype Annotation symbol Stock number DIOPT score
HibchRNAi VDRC w[1118]; P{GD11513}v40570 CG5044 v40570 9
MTPαRNAi VDRC w[1118]; P{GD11299}v21845 CG4389 v21845 8
RokRNAi GD VDRC w[1118]; P{GD1522}v3793 CG9774 v3793 9
RokRNAi TRiP BDSC y[1] v[1]; P{y[ + t7.7] v[ + t1.8] = TRiP.JF03225}attP2 CG9774 28797 9
Table 2. Drosophila stock description. VDRC: Vienna Drosophila RNAi Centre. BDSC: Bloomington 
Drosophila Stock center.
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synaptic” Cln3−/− isolates, relative to controls (Fig. 7B), suggesting a more synaptically-focussed response to 
altered CLN3 expression. Our in silico analysis added support for this model by highlighting specific sub-cascades 
under multiple pathways related to ROCK2 such as “Signalling by Rho Family GTPases” and “Rho A signalling” 
(Fig. 5B and C). These cascades regulate actin dynamics and cytoskeletal organization (as shown in Fig. 7C) and 
can impact synaptic structure and affect synaptic transmission. Figure 7D summarises previously published data 
generated by our laboratory where ROCK2 was identified to be upregulated in a range of conditions at early stages 
of disease progression2 and new synaptic data regarding its role in CLN3 disease. Thus, the conserved increased 
expression of ROCK2 in Cln3−/− mice, and in other related conditions and its ability to change degeneration, is 
highly suggestive of a potentially conserved contribution to synaptic vulnerability.
Thus, in order to investigate whether ROCK2 is capable of directly modulating the process of neurodegen-
eration in a CLN3-specific disease context in vivo, we again turned to the CLN3 Drosophila model. RNAi GD 
and RNAi TRiP fly lines for a ROCK2 ortholog were crossed to our established CLN3 recombinant Drosophila 
(see Table 2). Genetic downregulation of ROCK2 with two independently generated RNAi lines were tested and 
both were found to drastically improve their CLN3-induced small eye phenotype, although was more obvious 
with the TRiP library line (Fig. 7G–I). The total surface area of the eyes of the offspring (GMR-GAL4;UAS-CLN3/
Figure 7. CLN3 induced degeneration is suppressed by the downregulation of ROCK2 genetically and 
pharmacologically (A) ROCK2 protein/gene interactome represented with IPA showing that some of the 
interactors of ROCK2 are also altered in “crude” thalamic synaptosomes. (B) QWB bands and quantification 
of control and Cln3−/− synaptic and “non synaptic” fraction. Upregulation of ROCK2 is higher in synapses 
than in the non-synaptic fraction indicating a potential synaptic specific response. *P < 0.05 (T-student test). 
(C) “Signaling by Rho family GTPases” canonical pathway represented by IPA. Upregulation/activation of 
ROCK2 impacts in actin nucleation and polymerization that may disrupt actin dynamics in the synapse. (A&C) 
Coloured nodes illustrate proteins present in the thalamic dataset in Cln3−/− with respect WT. Nodes in grey 
represent proteins changed <20%, down-/up-regulated proteins by >20% are represented in green and red 
respectively, orange indicates predicted activation and blue; predicted inhibition. (D) ROCK2 upregulation at 
early stage of disease is a converved event across animal models of injury, two adult-onset neurodegenerative 
diseases (Huntington and Spinocerebelar ataxia)2 and two childhood neurodegenerative conditions (SMA 
and the lysosomal storage disorders-NCLs). (E and H) Representative light microscope images of Drosophila 
eyes and corresponding 200x zoom of eye structure of (A) Disease Model (DM) (B) DM + 1.5 mM Fasudil. 
(C) DM + Rok RNAi TRiP and (D) Control fly (Canton S). (I) Bar chart representing the % of normalized 
suppression calculated from the average eye surface areas of three independent experiments as “(x- average eye 
surface area of the disease model)/(average of eye surface area of the control - average eye surface area of disease 
model) × 100” for each of the three independent experiments. Scale bar = 100um. ***P < 0.001, *P < 0.05 
(One-way ANOVA and Tukey’s multiple comparison test as a post-hoc).
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RokRNAi) were non-significant with respect the control eyes and therefore the phenotype was fully-recued. 
Qualitatively, there was also an obvious reduction/absence of black patches (indicative of cell death), and clear 
recovery of the gross structure of the Drosophila compound eye. With the RNAi GD line the eye size was also 
improved (25.22% of recue) (Fig. 7I). Thus, experimental manipulation of ROCK2 was sufficient to modulate 
neurodegeneration in a CLN3 model in vivo. To exclude the possibility of the suppression effect being due to the 
dilution of GAL4 among two UAS transgenes, a control experiment was carried out, where the CLN3 recombi-
nant fly was crossed to a UAS-GFP line. No significant changes were detected in the eye of the offspring, indicat-
ing that the results showed in our RNAi experiments are likely a consequence of the downregulation of ROCK2.
The ROCK inhibitor Fasudil ameliorates CLN3-dependent neurodegeneration in vivo. 
Following the rescue of the CLN3-dependent eye degeneration by means of genetic tools we therefore wanted to 
test the possibility of targeting ROCK2 pharmacologically in Drosophila.
Several ROCK inhibitors have been characterized, but their specificity for individual ROCK kinases is still 
unclear. Fasudil is a small molecule that unspecifically inhibits ROCK2, originally discovered as a blocker of cere-
bral vasospasm in animal models67. Importantly, fasudil has been demonstrated to be safe and effective in clinical 
trials of cerebral vasospasm, pulmonary hypertension, Raynaud phenomenon and cancer68–73. Moreover, fasudil 
has previously been applied to murine models of SMA showing an improvement of the phenotype and lifespan of 
these mice65,66. However, fasudil also targets other kinases such as MAP4K4, PKC, PRKAA1 or PRKAA274, which 
are predicted to be also activated by IPA (Supplementary Fig. S8A). The activation of these kinases seem to have 
downstream consequences on biological functions relevant to NCL such as autophagy (Supplementary Fig. S8A) 
or and “Protein kinase A signalling” (Supplementary Fig. S8B and C). Given the success of the compound in 
mammalian systems65,66,73, including humans69,70, to date and the apparently conserved ROCK2 alterations across 
multiple-neurodegenerative paradigms, we decided to test Fasudil in CLN3 Drosophila (GMR-GAL4/UAS-CLN3). 
The drug was added into the fly food in order to obtain 1.5 mM of fasudil in the food and the Drosophila were 
raised as normal (see Methods). Pharmacological inhibition with fasudil caused a significant, albeit modest sup-
pression of the CLN3-derived eye phenotype. Quantification of eye surface areas confirmed a 17% rescue of the 
CLN3 eye phenotype in the treated animals (Fig. 7E,F and I). Thus, targeting of ROCK cascades with fasudil was 
sufficient to ameliorate neurodegeneration in a CLN3 model in vivo.
Discussion
Here we show what may be the first proteomic profiling carried out across multiple differentially vulnerable syn-
aptic populations at an early stage of disease progression. We have demonstrated that such unbiased proteomic 
mapping of distinct pre-synaptic populations coupled with in silico analysis, and in vivo rapid phenotypic screen-
ing in Drosophila, is an effective target-rich workflow for the identification of novel molecular alterations that 
regulate synaptic/neuronal stability.
Here we have confirmed that Cln3−/− murine pre-synaptic pathology appears to follow the same neuronal 
differential vulnerability pattern as other NCL subtypes12,14. We show that, at 13 months of age in Cln3−/− mice 
the synaptic pathology is more pronounced in the thalamus (although still <10%), followed by hippocampal 
pre-synaptic compartments, while cortical synaptic populations remain relatively unaffected (Fig. 1). iTRAQ 
proteomic and bioinformatics showed that differential synaptic pathology was also reflected at the molecular 
level, showing a progressive increase in the disruption of multiple canonical pathways correlating with our obser-
vations at the immunohistological level (Fig. 3B). Further analyses by means of complex pattern recognition soft-
ware identified alterations in the pre-synaptic proteome (identified by iTRAQ analysis of “crude” synaptosomes) 
that correlated with the assigned vulnerability status of pre-synaptic populations in the Cln3−/− mice. Pathway 
analysis highlighted perturbations in valine catabolism and rho signaling pathways, with proteins including 
HIBCH, HADHA and ROCK2 as key players, correlating with synaptic vulnerability. Furthermore, HIBCH and 
ROCK2 displayed a conserved direction of change in multiple neurodegenerative conditions (Figs 5E and 7D), 
and we have previously demonstrated that they can alter axonal degeneration in an injury dependent context2. 
Importantly, this suggests that not only do conserved pathways regulating degenerative processes exist, but they 
may be targetable across multiple conditions (Fig. 7D).
In contrast, no lysosomal specific pathways were identified in our in silico analysis in synapses, indicating 
that loss of CLN3 may be impacting in other pathways beyond lysosomal function. This is supported by studies 
in which CLN3 was found to be expressed in other locations such as in synaptosomes, lipid rafts, Golgi, mito-
chondria, glia and endothelial cells75–79, where it may play other roles such as regulation of oxidative stress78,80 
and glial function32,34 or blood-brain barrier homeostasis79. However, individual NCL and lysosomal-storage 
disorder-related proteins were identified, such as cathepsin D81, prosaposin82,83 and acid ceramidase84 confirming 
the veractity of the data generated.
By influencing the valine catabolic cascade through genetic disruption of HIBCH and HADHA it was pos-
sible to alter the CLN3 degenerative phenotype in Drosophila in vivo. Moreover, the further upstream in the 
catabolic cascade we intervened, the greater the resulting effect on disease phenotype. In humans, both HIBCH 
and HADHA deficiency cause infantile onset diseases with neurologic clinical scheme53,85,86. Crucially, this could 
indicate that perturbations in valine catabolic pathways might be a shared event across multiple neurodegenera-
tive conditions and therefore targets identified here may be transferable to other diseases.
Interestingly, the upregulation of ROCK2 has been reported in a range of conditions by our laboratory and 
others2,61,62,64 (Fig. 7D). ROCK2 upregulation seemed to be a more synaptic-specific perturbation (at least at early 
stages) in the Cln3−/− mice and its magnitude of change tracked across differentially vulnerable brain regions (i.e. 
Thalamus > Hippocampus > Cortex). Its genetic and/or pharmacological downregulation has also been shown 
to ameliorate the phenotype of several conditions including SMA, another relatively early onset neurodegener-
ative disease65,66. In this study we demonstrate for the first time that downregulation of ROCK2 also recues the 
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phenotype in a CLN3 in vivo model when manipulated genetically, and to a lesser degree with available pharma-
cological agents (Fig. 7E–I).
Cortical synaptic extracts from human patients have shown that ROCK2 was downregulated in JNCL patients 
with respect to controls (Supplementary Fig. S9). Nevertheless, the interpretation of the results from post mortem 
tissue is challenging as at end stage of the disease brain atrophy is much more pronounced, making it difficult 
to distinguish which molecular alterations are more likely to be causative, and which are a consequence of the 
ongoing degeneration taking place. ROCK2 upregulation could be a disease stage-specific change that contrib-
utes to the initiation of degenerative stimuli, and it is not necessarily globally upregulated throughout disease 
progression. It would be advantageous to study the molecular alterations and pathways taking place throughout 
the time-course of disease progression in NCL as this would further our understanding of the mechanisms under-
lying the initiation and progression of neurodegeneration. In general, ROCK2 appears to be an attractive target 
for the development of new therapeutic strategies, not only for NCL, but also in a wide range of more common 
neurodegenerative diseases to potentially halt or delay disease progression (Fig. 7D). There are currently multiple 
ROCK inhibitors with different degrees of specificity available68,74. However, in order to avoid off-target effects in 
future studies, it will be necessary to develop a compound that targets ROCK2 more specifically.
It would be of interest for future investigations to study the molecular overlaps between valine degradation 
and ROCK2 signaling pathways contributing to synaptic vulnerability. In silico analysis based on published liter-
ature, suggests potential overlaps, although the level of complexity in the published data allowing us to draw links 
between these candidates would require carefully planned experiments in order to unravel such interactions (See 
Fig. S10).
We suggest that common mechanisms regulating the process of neurodegeneration and/or vulnerability of 
synapses may occur across a range of neurodegenerative conditions triggered by different insults. Unlike more 
common adult-onset complex polygenetic diseases such as Alzheimer or Parkinson disease for which the genetic 
insult triggering the neurodegeneration is not well understood, the NCLs are monogenetic diseases for which 
there are available well-characterized mice models that more accurately replicate the human disease14,31,32,35,87,88. 
Here we demonstrate that we can use the NCLs as a model to study a specific neurodegenerative process (i.e. syn-
aptic loss) which is likely goverened by mechanisms which may indeed be conserved across multiple conditions 
ranging from injury through to chronic neurodegenerative conditions (i.e. Huntington disease and spinocerebel-
lar ataxia) and diseases of childhood (i.e. SMA and the NCLs).
The workflows highlighted here should not be viewed as a mass screening “stamp collecting” exercise. Instead 
it should be clear that combining mammalian model “–omic” screening of differentially vulnerable tissues with 
in silico candidate identification and in vivo phenotypic assessment in Drosophila is an efficient pipeline for elu-
cidating the mechanistic cascades governing neurodegenerative processes, and a “target-rich” way of identifying 
factors which are capable of modulating neurodegeneration, and therefore may be therapeutically targetable.
Materials and Methods
Tissue harvesting and processing. Ethics statement. All animal experiments were approved by a 
University of Edinburgh internal ethics committee and were performed under license by the UK Home Office 
(project license numbers 70/6567 and 70/7364).
Mice. Cln3−/− mice31 inbred on a C57BL/6 background for at least 10 generations and control (+/+) littermates 
resulting from heterozygous crosses were used in this study. Mice were genotyped as described in31. Five Cln3−/− 
and five wild-type control mice (WT) at 6.5 months and 12–13 months of age were used for immunohistochem-
istry experiment. Four Cln3−/− and four control mice (WT) at 12–13 months were used for the proteomics and 
biochemical experiments.
Human post mortem samples. Human brain samples were obtained from the Human Brain and Spinal Fluid 
Resource Center, Los Angeles and from The MRC London Neurodegenerative Disease Brain Bank, Institute of 
Psychiatry, Psychology & Neuroscience, King’s College London. Samples were obtained at routine autopsy with 
fully informed written consent by the families. Study protocols for the use of this human material were approved 
by the Ethical Research Committees of the Institute of Psychiatry under the approval numbers 223/00 and 181/02. 
All experiments using human tissue samples and/or derivatives of, were performed in accordance with the rel-
evant guidelines and regulations governing their storage, handling and disposal. Details about the samples are 
described in Supplementary Table S5.
Immunohistochemistry (IHC). Five Cln3−/− and five wild-type control mice (WT) at 6.5 months and 
12-13 months of age were terminated and brains rapidly removed and immersed for fixation in 4% paraformald-
hyde (pH 7.4). The IHC protocol used allows quantitative and qualitative comparisons between animal tissues as 
previously described in89,90. Please refer to Supplemental Experimental Procedures for more details.
Biochemical separation of neuronal compartments. Brains were harvested from six Cln3−/− and 
wild-type (WT) controls mice at 13 months old and briefly chilled in ice cold ACSF (125 mM NaCl, 26 mM 
NaHCO3, 25 mM glucose, 2.5 mM KCl, 1.25 mM NaH2PO4, 1 mM CaCl2, 4 mM MgCl2) before regional micro-
dissection. Thalamus, cortex (predominantly pre-/frontal) and hippocampus and were microdissected bilat-
erally12,17,91 pooled by mouse and immediately processed for “crude” synaptosome production as previously 
described2,17,92. Please refer to Supplemental Experimental Procedures for more details.
For the post mortem human samples, a portion of the total sample was obtained from frozen tissue (stored 
at −80 °C) and transferred in an eppendorf tube containing cold isotonic sucrose solution. Please refer to 
Supplemental Experimental Procedures for more details.
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Protein extraction. Mice. For iTRAQ proteomics, protein extraction from “crude” synaptosomes was car-
ried out as previously described in Fuller et al.93. Please refer to Supplemental Experimental Procedures for more 
details.
Human. “crude” synaptosomes were resuspended and homogenized in a solution containing 100 mM Tris-HCl, 
4% (w/v) SDS and 1% protease inhibitor cocktail (Roche). Samples were spun at 20,000 g and 4 °C for 20 minutes. 
Supernatant was aspirated and collected as extracted sample. Pellets and extracted samples were stored at −80 °C 
for QWB. Extracted samples concentration was determined using a BCA assay (Thermo).
Proteomic processing. Sample preparation and protein identification and quantification analysis by mass 
spectrometry was carried out as previously described in Fuller et al.93. Please refer to Supplemental Experimental 
Procedures for more details.
Quantitative fluorescent western blotting (QWB). QWB was performed as previously described in 
refs2,91,92,94,95. Briefly, samples were denatured in NuPage® LDS Sample buffer 4X (Invitrogen, UK) at 98 °C and 
15ug of protein loaded and run on 4–12% Bis-Tris gel (Invitrogen). Accuracy of loading and protein estima-
tion was confirmed by total protein analysis of Instant Blue (Expedeon) stained gels as previously described94. 
Protein transfer to a polyvinylidene fluoride (PDVF) membrane was carried out using the I-Blot® transfer sys-
tem (Invitrogen, UK). Membranes were incubated with Odyssey blocking buffer (Li-Cor) for 30 minutes. Next, 
membranes were incubated in primary antibodies overnight at 4 °C and secondary antibodies for 1 h at room 
temperature. Please refer to Supplemental Experimental Procedures for more details.
In silico proteomic analysis. BioLayout Express 3D. BioLayout software incorporates a complex pattern 
recognition algorithm which groups protein data based only on expression profile. It allows the visualization and 
graphing of expression trends of co-expressed proteins to allow better characterization and understanding of 
complex large datasets44. Please refer to Supplemental Experimental Procedures for more details.
Enrichment analysis. To obtain an indication of the level of sample enrichment afforded through the process of 
synaptosome production, un-filtered mass spectrometry data was processed using The Database for Annotation, 
Visualization and Integrated Discovery (DAVID) software (available at http://david.abcc.ncifcrf.gov). DAVID pro-
vides a relatively comprehensive set of functional annotation tools for large data set interpretation96,97. DAVID was 
also used to characterize the functions associated to the protein clusters correlating to vulnerability mapped using 
BioLayout. For analysis to confirm synaptic protein enrichment we have applied a cut off of four fold as previously 
described in98 (see Table 1).
Ingenuity Pathway analysis. To obtain further insight into potential cellular pathways that may be perturbed 
in the Cln3−/− thalamic pre-synaptic compartments compared to control mice, the Ingenuity Pathways Analysis 
(IPA) application (Ingenuity Systems) was used, as previously described2,91,92,99. Please refer to Supplemental 
Experimental Procedures for more details.
Phenotypic assessment methods and Drosophila husbandry. Drosophila mouse orthologs for 
candidate proteins were identified using DRSC Integrative Ortholog Prediction Tool (DIOPT)100 and RNAi lines 
were chosen from Flybase and obtained from Vienna Drosophila stock centre (VDSC) and from Bloomington 
Drosophila Stock Centre (BDSC) (see Table 2). UAS-CLN3 mutant fly was donated by Richard Tuxworth57. A 
stock carrying GMR-GAL4 and UAS-CLN3 on the second chromosome was established by conventional recombi-
nation methods and used as a tester line for the screen (GMR-GAL4;UAS-CLN3/CyO GFP). RNAi candidate lines 
were crossed to this line and the F1 progeny was assessed for suppression or enhancement of the CLN3-derived 
small and rough eye phenotype. To have a quantitative read out of the severity of the phenotypes obtained in our 
experiments we measured the eye surface area, as previously described101. Stocks were maintained on standard 
cornmeal food at room temperature. For all the crosses, flies were raised at 25 °C in a circadiarian light incubator. 
Details of the lines used can be found in Table 2.
Fasudil drug assay. The rock inhibitor used was Fasudil, Monohydrochloride Salt (LC laboratories, 
F-4660), which was previously used in mice models of SMA improving survival and skeletal muscle develop-
ment65. GMR-GAL4 x UAS-CLN3 crosses were raised in Nutri-Fly instant food (Genesee Scientific, 66-118) con-
taining 1.5 mM of Fasudil Monohydrochloride Salt and blue food colouring diluted in water, as described in102. 
Eyes of the offspring were photographed and total surface area was measured with Image J. Suppression of the 
CLN3-degenerative eye were calculated from 3 independent experiments as “(x- average eye surface area of the 
disease model)/(average of eye surface area of the control − average eye surface area of disease model) × 100” for 
each experiment.
Imaging. Immunohistochemistry. Micrographs were taken with Leica DMRB × 5/0.12 objective and 
AxioCam HRC Zeiss from the following brain regions: 1. The thalamic nuclei ventral posterior medial/ventral 
posterior lateral thalamic nucleus (VPM/VPL) and the dorsal lateral geniculate nucleus (LGNd); 2. Their respec-
tive cortical projections in the primary somatosensory cortex (S1BF) and primary visual cortex (V1) respectively, 
and 3; the hippocampal stratum radiatum and stratum oriens (See Fig. 1A). Immunoreactivity measurements 
were carried out using a thresholding image analysis in Image J (National Institute of Health, Bethesda, MD), 
USA), as previously described32,34,103. Thirty non-overlapping images (x40) were taken, on three consecutive sec-
tions, through the brain areas described above. All parameters including lamp intensity, video camera setup and 
calibration were kept constant throughout image capturing.
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Drosophila eye images. For the HIBCH and HADHA experiments fruit fly eye images were photographed with a 
Nikon D5100 camera attached to a SZX9 Nikon stereomicroscope. For the ROCK2 experiments eye images were 
taken with an AxioCam ERc 5 s Rev.2 attached to a Zeiss Stemi 305 trino stereomicroscope. Images were analyzed 
with Image J software (National Institute of Health, Bethesda, MD, USA) as previously described in101.
Data analysis and figure production. QWB data was analysed using Odyssey software as per manufac-
tures guidelines and as previously described2,17,104. Data was graphed and statistical comparisons for IHC thresh-
olding, QWB protein intensity and Drosophila eye surface area quantification were carried out using GraphPad 
Prizm as previously described91,101. For QWB and IHC Student’s T test was applied. For Drosophila eye quantifi-
cations one-way ANOVA was carried out followed by Tukey’s multiple comparison test as a post-hoc when a sig-
nificant difference was found in the ANOVA. P values < 0.05 were considered to be statistically significant for all 
analyses (*P < 0.05; **P < 0.01; ***P < 0.001). Statistical analysis of proteomic data was automatically carried out 
by MASCOT. P & Benjamini values to determine enrichment were automatically calculated by DAVID software 
(see above and http://david.abcc.ncifcrf.gov). P values/Fishers exact tests for pathway and networking analysis 
were automatically determined by IPA (see above and http://www.ingenuity.com/). Heatmap representing the dif-
ferentially expressed proteins and pathways across brain regions was produced using “R” (http://www.R-project.
org)105.
Availability of data and material. The raw datasets used and/or analysed during the current study are 
available from the corresponding author on reasonable request.
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